Navigation Links
BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
Date:6/29/2009

LYNBROOK, N.Y., June 29 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced today that it was added to the Russell 3000 and Russell 2000 Indexes effective at the close of the U.S. markets on June 29, 2009. The Russell family of U.S. indexes is reconstituted annually and is designed to be a comprehensive representation of the investable U.S. equity market.

The Russell 3000 Index measures the performance of the largest 3000 U.S. companies representing approximately 98 percent of the investable U.S. equity market. Membership in the Russell 3000 Index results in automatic inclusion in either the large-cap Russell 1000 Index or the widely used small-cap Russell 2000. The Russell 2000 includes approximately 2000 of the smallest securities based on a combination of their market cap and current index membership and is constructed to represent a true small-cap opportunity set.

Russell indexes are widely used by fund managers for index funds and as benchmarks for both passive and active investment strategies.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX product in Europe.

More information about the company may be found on its website at

SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
2. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
3. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
4. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
5. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
6. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
7. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
8. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
9. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
10. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
11. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 In an article ... UPMC Center for Health Security review the clinical aspects ... be used as bioweapons. The article, "Clinical Management of ... on the website of the New England Journal ... Eric Toner , and Tom Inglesby—review the clinical ...
(Date:3/4/2015)... -- Brooklyn residents now have a new place to go ... Nunzio Saulle , M.D., a board-certified physiatrist, is ... Physical Medicine and Rehabilitation (PM&R) practice in ... Health Plus Management, LLC is managing the day-to-day operations ... Avenue. This new PM&R practice will treat patients suffering ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Biomarkers - Technologies, ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:3/4/2015)... , March 4, 2015 /CNW/ - Resverlogix ... it has completed a collaborative research program ... analytics.  Using Fast Collective Evolution Technology (FACET), ... including all measurements obtained from each of ... Phase 2 clinical trials ASSERT, SUSTAIN and ...
Breaking Biology Technology:Latest Clinical Information On Bioterrorism Threats 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... ST. LOUIS, Oct. 25 Sigma-Aldrich(TM) (Nasdaq:,SIAL), a ... biotechnology products to the world,s researchers, and Oxford,BioMedica ... today that,they received a key order confirming the ... BioMedica and licensed exclusively in,the research field to ...
... Study Planned, WESTMINSTER, Colo., Oct. 25 ... company focused on,the development and commercialization of small ... that results from three PDX,studies were presented as ... 2007 in San Francisco, California. The posters,described the ...
... XTL Biopharmaceuticals,Ltd. (NASDAQ: XTLB )(LSE: XTL)(TASE: XTL) ... with institutional investors relating to,a private placement of ... of,ordinary shares, represented by American Depositary Receipts (ADRs). ... Sciences Fund, Quogue,Capital LLC, SCO Capital Partners and ...
Cached Biology Technology:Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 3Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 2Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 3Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 4XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 2XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 3
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... BEER-SHEVA, ISRAEL, May 3, 2010 Ben-Gurion University ... strain which produces large amounts of a polyunsaturated fatty ... blood cholesterol level, reducing the risk for heart attacks. ... Biotechnology Lab in the Jacob Blaustein Institutes for Desert ...
... keep the planet cool, but rising levels of carbon dioxide ... According to a new study by researchers at the Carnegie ... of the warming from increased carbon dioxide is due to ... to carbon dioxide,s better-known effect as a heat-trapping greenhouse gas. ...
... (May 3, 2010) Advances in energy conservation, better ... breakthroughs in understanding diseases: These are just a few ... be enabled by an upgrade to the Advanced Photon ... Argonne National Laboratory., DOE today announced formal approval for ...
Cached Biology News:Ben-Gurion U researchers isolate microalgal strain that could reduce cholesterol 2CO2 effects on plants increases global warming 2CO2 effects on plants increases global warming 3Upgrade to advanced photon source announced by DOE 2Upgrade to advanced photon source announced by DOE 3
... Ingredients (g/L):,Tryptone, 10 ,Yeast extract, 5 ... 0.3 ,Ferric ammonium citrate, 0.5 ,IPTG, ... water soluble, autoclavable chromogenic substrate for ... by -galactosidase generates a black insoluble ...
... form: Lyophilized powder containing ... Unit Definition: One unit ... 2-phosphoglycerate to phospho(enol)pyruvate per ... 25 C. Chem comp: ...
... CoA ligase (AMP forming), Acetate thiokinase ... content. Physical form: Lyophilized powder ... reduced glutathione Preparation Unit Definition: ... S-acetyl coenzyme A from acetate, ATP and ...
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... mm, No. of sidearm 4 ...
Biology Products: